Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, MD
Published Online: Monday, Jun 09, 2014



Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0
Community Practice Connections™: Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian CancerJun 24, 20172.0
Publication Bottom Border
Border Publication